Trials / Not Yet Recruiting
Not Yet RecruitingNCT07374549
SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma
A Randomized, Open-Label, Controlled, Multicenter Phase 2 Trial of SYS6002 Versus PADCEV in Patients With Advanced Urothelial Carcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, open-label, controlled, multicenter phase II clinical trial, which aims to evaluate the safety and efficacy of SYS6002 versus enfortumab vedotin in the treatment of participants with advanced urothelial carcinoma. This study has not yet been submitted for ethical review. The current registration is a pre-registration. Recruitment will be initiated only after formal approval is obtained from the relevant Ethics Committee or Institutional Review Board.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYS6002 | SYS6002 by intravenous (IV) |
| DRUG | enfortumab vedotin | 1.25 mg/kg by IV on Day 1、8、15, every 28 days. |
Timeline
- Start date
- 2026-06-20
- Primary completion
- 2028-06-01
- Completion
- 2028-12-01
- First posted
- 2026-01-29
- Last updated
- 2026-01-29
Source: ClinicalTrials.gov record NCT07374549. Inclusion in this directory is not an endorsement.